latest news releases from the newsroom
MEDirect Latino, Inc.
MEDirect Latino Initiates System Migration, Creates Greater Customer Service Efficiencies
POMPANO BEACH, Fla., June 5, 2007 (PRIME NEWSWIRE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (www.medirectlatino.org), the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community, today announced the Company is in the final stages of its migration to a superior customer service software operating platform with proprietary features for customer tracking, forecasting, service, medical billing and collections. The proprietary platform includes electronic processing of medical verifications, eligibility and medical billing which will substantially reduce Medicare's reimbursement payment cycles (DSO), while increasing the percentage of collectables.
StockGuru.com Announces Profile Coverage of Harvard Learning Centers
DALLAS, June 5, 2007 (PRIME NEWSWIRE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has initiated Profile Coverage of Harvard Learning Centers, Inc. (Pink Sheets:HVLN). Harvard Learning Centers offers training programs for both the mind and body of teenagers and young adults. Its historic focus has been the offering of SAT-ACT test preparation programs that help high school students succeed. SAT and ACT are standardized tests used by most U.S. colleges and universities for admission and placement decisions and scholarship eligibility. For SAT-ACT test preparation, the Harvard Learning Centers, Inc. offers classroom and online courses along with private tutoring.
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim results from a Phase I clinical trial of the companies' heat shock protein 90 (Hsp90) inhibitor, IPI-504, in patients with relapsed, refractory gastrointestinal stromal tumors (GIST) and other advanced soft tissue sarcomas. The data, presented at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), indicate that IPI-504 continues to be well tolerated and to show evidence of biological activity.